Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms

References

• Post RM. The impact of bipolar depression. J Clin Psychiatry 2005; 66 (Suppl 5):5–10.
   PubMedGoogle Scholar
• Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, . Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Psychiatry 2006; 163 (2):217–24.
   Google Scholar
• Rosa AR, Reinares M, Michalak EE, Bonnin CM, Sole B, Franco C, . Functional impairment and disability across mood states in bipolar disorder. Value Health 2010; 13 (8):984–8.
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller H-J, . The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biolo Psychiatry 2010; 11 (2):81–109.
   PubMed Web of Science ®Google Scholar
• Zornberg G, Pope HGJ. Treatment of depression in bipolar disorder: new directions for research. J Clin Psychopharmacol 1993; 13 (6):397–408.
   PubMed Web of Science ®Google Scholar
• Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, . A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20 (6):607–14.
   PubMed Web of Science ®Google Scholar
• Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, . World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002; 3 (3):115–24.
   PubMedGoogle Scholar
• Shelton RC, Stahl SM. Risperidone and paroxetine given singly and in combination for bipolar depression. J Clin Psychiatry 2004; 65 (12):1715–9.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, . A randomized double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. J Psychiatry 2005; 162 (7):1351–60.
   Google Scholar
• Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194 (1):4–9.
   PubMed Web of Science ®Google Scholar
• Grandjean EM, Aubry JM. Lithium: updated human knowledge using an evidence-based approach: part III: clinical safety. CNS Drugs 2009; 23 (5):397–418.
   PubMed Web of Science ®Google Scholar
• Young A, McElroy S, Bauer M, Philips N, Chang W, Olausson B, . A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71 (2):150–62.
   PubMed Web of Science ®Google Scholar
• Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, . Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26 (6):600–9.
   PubMed Web of Science ®Google Scholar
• Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, . Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28 (1):13–20.
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Calabrese J, Ketter T, Sachs G, Bowden C, . Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60 (11):1079–88. Erratum in: Arch Gen Psychiatry 2004; 61 (2):176.
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999;60 (2):79–88.
   PubMed Web of Science ®Google Scholar
• Kemp DE, Calabrese JR, Eudicone JM, Ganocy S, Tran QV, McQuade RD, . Predictive value of early improvement in bipolar depression trials: A post-hoc pooled analysis of two 8-week aripiprazole studies. Psychopharmacol Bull 2010; 43 (2):5–27.
   Google Scholar
• Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, . The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007; 68 (6):843–53.
   PubMed Web of Science ®Google Scholar
• Berman R, Fava M, Thase M, Swanink R, McQuade R, Carson W, . Aripiprazole augmentation in major depression: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums 2009; 14 (4):197–206.
   PubMed Web of Science ®Google Scholar
• Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, . The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2008; 28 (2):156–65.
   PubMed Web of Science ®Google Scholar
• Kilts CD, Wade AG, Andersen HF, Schlaepfer TE. Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 2009; 10 (6):927–36.
   PubMed Web of Science ®Google Scholar
• Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states. Acta Psychiatr Scand 1975; 51 (3):161–70.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382–9.
   PubMed Web of Science ®Google Scholar
• Bech P, Tanghoj P, Andersen HF, Overo K. Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. Psychopharmacology (Berlin) 2002; 163 (1):20–5.
   PubMed Web of Science ®Google Scholar
• Bech P. Rating scales in depression: limitations and pitfalls. Dialogues Clin Neurosci 2006; 8 (2):207–15.
   PubMedGoogle Scholar
• Carmody TJ, Rush AJ, Bernstein I, Warden D, Brannan S, Burnham D, . The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006; 16 (8):601–11.
   PubMed Web of Science ®Google Scholar
• Stein D, Baldwin D, Dolberg O, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006; 67 (11):1741–6.
   PubMed Web of Science ®Google Scholar
• Goldberg JF, Perlis RH, Bowden CL, Thase ME, Miklowitz DJ, Marangell LB, . Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. J Psychiatry 2009; 166 (2):173–81.
   Google Scholar
• Swann AC, Gerard Moeller F, Steinberg JL, Schneider L, Barratt ES, Dougherty DM. Manic symptoms and impulsivity during bipolar depressive episodes. Bipolar Disord 2007; 9 (3):206–12.
   PubMed Web of Science ®Google Scholar
• Frye MA, Helleman G, McElroy SL, Altshuler LL, Black DO, Keck PE Jr. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. J Psychiatry 2009; 166 (2):164–72.
   Google Scholar
• Frye MA, Eudicone J, Pikalov A, McQuade RD, Marcus RN, Carlson BX. Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials. J Clin Psychopharmacol 2008; 28 (2):243–5.
   PubMed Web of Science ®Google Scholar